Workflow
透景生命收盘上涨1.37%,滚动市盈率57.87倍,总市值22.86亿元

Company Overview - The company, Shanghai TuoJing Life Technology Co., Ltd., focuses on the research, production, and sales of in vitro diagnostic products under its own brand [1] - Main products include in vitro diagnostic reagents, instruments, and service revenue [1] - The company actively participates in various health-themed public welfare activities and has received multiple awards for social responsibility, including the "Social Public Welfare Award" from the China Cancer Foundation [1] Financial Performance - For Q1 2025, the company reported revenue of 74.89 million yuan, a year-on-year decrease of 19.53% [1] - Net profit for the same period was 471,700 yuan, showing a significant year-on-year increase of 110.51% [1] - The gross profit margin was reported at 63.66% [1] Market Position - As of May 27, the company's stock closed at 14.02 yuan, with a PE ratio of 57.87 times [1] - The total market capitalization of the company is 2.286 billion yuan [1] - In comparison, the average PE ratio for the medical device industry is 49.11 times, with a median of 35.89 times, placing the company at the 93rd position in the industry ranking [1][2] Institutional Holdings - As of Q1 2025, five institutions hold shares in the company, with a total of 28.0388 million shares valued at 403 million yuan [1]